1. Helpap B, Egevad L, The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006,449-622
2. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI, Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radicalprostatectomy. Urology 2008,72-172
3. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI, Do adenocarcinomas of the prostate with Gleason score (gs) &le6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012,36-1346
4. Lotan TL, Epstein JI, Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol 2009,40-471
5. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S, Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014,15-234
6. Pierorazio PM, Walsh PC, Partin AW, Epstein JI, Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013,111-753
7. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA, A contemporary prostate cancer grading system: a validated alternative to Gleason score. Eur Urol 2016,69-428